Cabaletta Bio Q2 net loss widens to $51.0 million; cash rises to $225.1 million
Cabaletta Bio reported a second-quarter 2026 net loss of $51.0 million, up from $45.1 million a year earlier, as research and development expenses rose to $44.4 million from $37.6 million. Cash, cash equivalents and short-term investments rose to $225.1 million at June 30, 2026, helped by a May 2026 registered direct offering, and the company expects this to fund operations into mid-2027.
Key points
- Net loss was $51.0 million for the quarter ended June 30, 2026, versus $45.1 million for the same period in 2025.
- Net loss per share was $0.34, compared with $0.73 a year earlier.
- R&D expenses were $44.4 million versus $37.6 million; G&A expenses were $7.6 million versus $8.3 million.
- Cash and short-term investments were $225.1 million, up from $133.6 million at December 31, 2025; the company expects to fund operations into mid-2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.